A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production

Upper Respiratory Tract Infections Clinical Trial

Official title:

A Single Centre, Partially Blinded, Randomised Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production in Healthy Human Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03198676
• Other study ID #: PrEP-001-104
• Status: Completed
• Phase: Phase 1
• First received: June 15, 2017
• Last updated: June 30, 2017
• Start date: May 8, 2017
• Est. completion date: May 24, 2017

Study information

• Verified date: June 2017
• Source: Prep Biopharm Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A safety study to compare the effect of two different formulations of PrEP-001 nasal powder when dosed in healthy subjects

Description:

A single centre, randomised, partially blinded placebo-controlled repeat dose study in healthy male subjects to compare the effect of two different formulations of PrEP-001 nasal powder on nasal mucosal and serum cytokine profiles when dosed for up to five days in health subjects and provide additional safety and tolerability information on active PrEP-001 nasal powder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: May 24, 2017
• Est. primary completion date: May 24, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy males

• Aged 18 to 65 years

• A body weight of >50 kg and body mass index .18.0 to <32.0 kg/m2

• Must be willing and able to communicate and participate in the whole study

• Must provide written informed consent

• Must agree to use an adequate method of contraception

Exclusion Criteria:

• Subjects who have received any IMP in a clinical research study within the previous 3 months

• Subjects who are study site employees, or immediate family members of a study site or sponsor employee

• Subjects who have previously been enrolled in this study

• History of any drug or alcohol abuse in the past 2 years

• Regular alcohol consumption >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

• Current smokers and those who have smoked within the last 12 months. A confirmed positive urine cotinine test at screening and admission

• Current smokers of e-cigarettes and nicotine replacement products and those who have smoked these products within the last 12 months

• Subject who have significant history of any tobacco use at any time (total =10 pack years history)

• Subjects who do not have suitable veins for multiple venepunctures as assessed by the investigator at screening

• Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1)

• Positive drugs of abuse test result (drugs of abuse tests are listed in Appendix 1)

• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results

• History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, or psychiatric disorder, as judged by the investigator

• Any chronic medical condition that could significantly reduce the ability of the subject to participate in the study or pose a safety concern eg unstable angina, uncontrolled diabetes mellitus, anaemia

• Any concurrent serious illness (eg diagnosis of severe depression, pulmonary hypertension, history of malignancy) that may interfere with a subject completing the study. Basal cell carcinoma within 5 years of initial diagnosis or with evidence of recurrence is also an exclusion

• Any finding in the medical history review, physical examination (including nasal exam with nasal speculae), screening investigations, that in the opinion of the investigator would compromise the subject's ability to safely complete the study

• Has experienced upper or lower respiratory infection (viral, fungal or bacterial) that resolved less than 4 weeks before Day 1

• Has required antibiotic treatment for a lower respiratory tract infection in the 3 months prior to the study

• Subjects with a significant nasal condition eg Wegener's granulomatosis, that could interfere with study assessments

• Any significant abnormality altering the anatomy of the nose or nasopharynx on examination

• Any nasal or sinus surgery within 6 months of Day 1

• Any clinically significant history of epistaxis (nosebleeds) within the last 12 months and/or history of being hospitalised due to epistaxis on any previous occasion

• History or evidence of autoimmune disease or known immunodeficiency of any cause - with the exception of atopic eczema/atopic dermatitis. Subjects with clinically mild atopic eczema/atopic dermatitis may be included at the Investigator's discretion (eg if there is no regular use of topical steroids, no eczema in cubital fossa)

• Subjects with known history of Immunosuppression or known chronic viral infection

• Has active seasonal or perennial nasal/pharyngeal allergies at screening visit; or anticipates to have such symptoms during the study duration; or has had symptoms in the 4 weeks prior to Day 1

• Presence or history of clinically significant allergy requiring treatment (including food or drug allergy), as judged by the investigator

• Known allergy or adverse reaction history to formulation components

• Donation or loss of greater than 400 mL of blood within the previous 3 months

• Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration (see Section 11.4). Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor

• Failure to satisfy the investigator of fitness to participate for any other reason

Related Conditions & MeSH terms

• Respiratory Tract Infections
• Upper Respiratory Tract Infections

Intervention

Drug:
• PrEP-001 6.4 mg
6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
• PrEP-001 6.4 mg
6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
• PrEP-001 3.2 mg
3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
• Placebo
2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device

Locations

Country	Name	City	State
United Kingdom	Quotient Clinical	Nottingham

Sponsors (1)

Lead Sponsor	Collaborator
Prep Biopharm Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in baseline in nasal mucosal secretions and serum cytokine concentrations	Changes from baseline in nasal mucosal secretions and serum cytokine concentrations when dosed for up to 5 days with 2 different formulations of PrEP 001 Nasal Powder (ie 6.4 mg Formulation B vs 6.4 mg Formulation A)	5 days
Secondary	Changes in baseline in nasal mucosal secretions and serum cytokine concentrations	Changes from baseline in nasal mucosal secretions and serum cytokine concentrations when dosed for up to 5 days with PrEP 001 Nasal Powder 6.4 mg Formulation B and matching placebo Formulation B	5 days
Secondary	Changes in baseline in nasal mucosal secretions and serum cytokine concentrations	Changes from baseline in nasal mucosal secretions and serum cytokine concentrations when dosed for up to 5 days with PrEP-001 Nasal Powder (3.2 mg and 6.4 mg Formulation B	5 days
Secondary	Assessment of safety parameters	Assessment of the following safety variables: physical examination, safety laboratory tests, vital signs, ECGs and AEs (Formulation B vs Formulation A)	5 days